Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes

Journal of Atherosclerosis and Thrombosis
Takahisa HiroseJ-BENEFIT study group

Abstract

Our previous "J-BENEFIT (Japan BEzafibrate cliNical EFfectIveness and Tolerability)" study demonstrated that bezafibrate improves blood lipid profiles and glucose control in dyslipidemic patients with diabetes. However, bezafibrate did not significantly improve low-density lipoprotein cholesterol (LDL-C), although some patients showed decreases while others showed increases in the LDL-C levels. Therefore, a subgroup analysis of the J-BENEFIT study was conducted to identify factors influencing the bezafibrate-induced changes in the LDL-C levels. Of the 3,316 patients in the J-BENEFIT study, 2,116 not treated with other lipid-lowering drugs were enrolled in the current study, and the effects of 24-week treatment with bezafibrate on the LDL-C levels were analyzed. A reduction in the LDL-C level of ≥ 25% occurred in 253 patients, and a logistic-regression analysis was used to identify factors associated with this improvement. Among the 2,116 overall patients, bezafibrate treatment significantly increased the LDL-C levels from 123.9±36.7 to 125.7±31.3 mg/dL. The subanalysis showed that the treatment responses varied according to the baseline LDL-C level, with significant decreases in the ≥ 160 and ≥ 140-<160 mg/dL groups, no signifi...Continue Reading

References

Jun 28, 2001·Journal of Atherosclerosis and Thrombosis·T NagaiM Mori
May 9, 2002·Atherosclerosis·Juan A Gómez-GeriqueUNKNOWN ATOMIX Investigators
Jan 17, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Tsutomu HiranoGen Yoshino
Jun 9, 2005·Journal of Atherosclerosis and Thrombosis·Hidenori AraiToru Kita
Jun 25, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Keita SanoKiyotaka Kugiyama
Sep 16, 2011·The Annals of Pharmacotherapy·Kandace L AmendAndrew McAfee

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.